Home » Stocks » Anavex Life Sciences

Anavex Life Sciences Corp. (AVXL)

Stock Price: $5.73 USD 0.47 (8.94%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $5.75 +0.02 (0.35%) Oct 23, 7:57 PM

Stock Price Chart

Key Info

Market Cap 344.89M
Revenue (ttm) n/a
Net Income (ttm) -24.19M
Shares Out 60.19M
EPS (ttm) -0.46
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $5.73
Previous Close $5.26
Change ($) 0.47
Change (%) 8.94%
Day's Open 5.37
Day's Range 5.30 - 5.80
Day's Volume 2,102,894
52-Week Range 2.20 - 6.31

More Stats

Market Cap 344.89M
Enterprise Value 317.27M
Earnings Date (est) Dec 14, 2020
Ex-Dividend Date n/a
Shares Outstanding 60.19M
Float 57.84M
EPS (basic) -0.42
EPS (diluted) -0.46
FCF / Share -0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 7.35M
Short Ratio 10.80
Short % of Float 12.70%
Beta 1.58
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 12.82
Revenue n/a
Operating Income -29.93M
Net Income -24.19M
Free Cash Flow -17.57M
Net Cash 27.62M
Net Cash / Share 0.46
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -61.12%
ROE -122.52%
ROIC 1,193.30%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(126.88% upside)
Current: $5.73
Target: 13.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-29.11-19.33-15.68-15.59-7.11-2.97-2.14-4.32-6.17-5.64
Net Income-26.29-17.25-13.46-14.74-12.11-9.97-3.70-8.30-7.31-8.78
Shares Outstanding48.9144.6640.8435.1518.589.807.987.046.295.36
Earnings Per Share-0.54-0.39-0.33-0.42-0.65-1.02-0.48-1.16-1.16-1.64
Operating Cash Flow-18.53-12.58-9.02-9.24-4.23-2.66-0.78-1.69-3.80-4.59
Capital Expenditures----------
Free Cash Flow-18.53-12.58-9.02-9.24-4.23-2.66-0.78-1.69-3.80-4.60
Cash & Equivalents22.1922.9827.499.2415.297.260.350.010.130.26
Total Debt----
Net Cash / Debt22.1922.9827.499.2415.217.070.13-0.29-0.73-2.23
Book Value20.2922.3224.256.3112.810.19-2.46-2.88-1.14-2.96
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Anavex Life Sciences Corp.
Country United States
Employees 16
CEO Christopher U. Missling

Stock Information

Ticker Symbol AVXL
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: AVXL


Anavex Life Sciences, a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase II clinical trials to treat Parkinson's disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer's and Parkinson's diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.